Amgen’s Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers
September 9, 2019
0
Amgen's Outperforming After being boxed in, for the past couple of weeks, Amgen’s (AMGN) stock finally outperformed. The firm was outperforming silently with regard to its financial results, sciences, technologies, pipeline products and multiple newly approved products drugs. In the News Amgen's Product AMG-510 Amgen announced new data from its ongoing Phase 1 study evaluating its unique cancer product AMG . . . This content …